newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted